ACPLP
RGNX icon

ACT Capital Partners, L.P.’s Regenxbio RGNX Stock Holding History

ACT Capital Partners, L.P.’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$395K Buy
+52,500
New +$533K 0.26% 39

Other funds holding RGNX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
GSK plc
GSK plc London $497M AUM 35.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Savant Capital
Savant Capital Rockford, Illinois $35B AUM 15.18% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

ACT Capital Partners, L.P.'s RGNX Position: Q3 2026 in Review

ACT Capital Partners, L.P. opened a new position in Regenxbio (RGNX) in Q3 2026: 52,500 shares worth $395K. The stake represents 0.26% of the portfolio and ranks #39 among its holdings.

53 funds tracked by Wall St. Rank hold RGNX as of Q3 2026.

  • ACT Capital Partners, L.P. held 52,500 shares of Regenxbio worth $395K as of Q3 2026.
  • Regenxbio was a new ACT Capital Partners, L.P. position in Q3 2026.
  • Regenxbio made up 0.26% of ACT Capital Partners, L.P.'s portfolio in Q3 2026, its #39 holding.
  • 53 funds tracked by Wall St. Rank held Regenxbio as of Q3 2026.

Based on ACT Capital Partners, L.P.'s 13F filing for Q3 2026, filed 6 Nov 2026.